Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest

Molecular and Cellular Biology

Volumn 27, Issue 11, 2007, Pages 4166-4178

  Giono, Luciana E ^a   Manfredi, James J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 2; DACTINOMYCIN; DOXORUBICIN; LYSINE; NUTLIN 3; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; SERINE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACETYLATION; ARTICLE; CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL STRESS; CONTROLLED STUDY; DNA BINDING; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE REPRESSION; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INHIBITION KINETICS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; TARGET CELL DESTRUCTION;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CELL CYCLE; CELL LINE; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DACTINOMYCIN; DOXORUBICIN; HUMANS; IMIDAZOLES; PIPERAZINES; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-MDM2; RESPONSE ELEMENTS; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34347351282     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01967-06     Document Type: Article

References (57)

1. Appella, E., and C. W. Anderson. 2001. Post-translational modifications and activation of p53 by genotoxic stresses. Eur. J. Biochem. 268:2764-2772.
2. Ashcroft, M., Y. Taya, and K. H. Vousden. 2000. Stress signals utilize multiple pathways to stabilize p53. Mol. Cell. Biol. 20:3224-3233.
3. 1 arrest that is suppressed by MDM2. J. Biol. Chem. 275:31883-31890.
4. Brown, D. R., C. A. Thomas, and S. P. Deb. 1998. The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell-cycle- inhibitory function induces tumorigenesis. EMBO J. 17:2513-2525.
5. Brugarolas, J., C. Chandrasekaran, J. I. Gordon, D. Beach, T. Jacks, and G. J. Hannon. 1995. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377:552-557.
6. 2 arrest after DNA damage. Science 282:1497-1501.
7. Chang, D., F. Chen, F. Zhang, B. C. McKay, and M. Ljungman. 1999. Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest. Cell Growth Differ. 10:155-162.
8. Child, E. S., and D. J. Mann. 2006. The intricacies of p21 phosphorylation: protein/protein interactions, subcellular localization and stability. Cell Cycle 5:1313-1319.
9. Cipriano, S. C., and Y. Q. Chen. 1998. Insensitivity to growth inhibition by TGF-pi correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. Oncogene 17:1549-1556.
10. Craig, A. L., L. Burch, B. Vojtesek, J. Mikutowska, A. Thompson, and T. R. Hupp. 1999. Novel phosphorylation sites of human tumour suppressor protein p53 at Ser20 and Thr18 that disrupt the binding of mdm2 (mouse double minute 2) protein are modified in human cancers. Biochem. J. 342(Pt. 1): 133-141.
11. Dang, J., M. L. Kuo, C. M. Eischen, L. Stepanova, C. J. Sherr, and M. F. Roussel. 2002. The RING domain of Mdm2 can inhibit cell proliferation. Cancer Res. 62:1222-1230.
12. Deng, C., P. Zhang, J. W. Harper, S. J. Elledge, and P. Leder. 1995. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G, checkpoint control. Cell 82:675-684.
13. de Rozieres, S., R. Maya, M. Oren, and G. Lozano. 2000. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 19:1691-1697.
14. Espinosa, J. M., R. E. Verdun, and B. M. Emerson. 2003. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol. Cell 12:1015-1027.
15. Estanyol, J. M., M. Jaumot, O. Casanovas, A. Rodriguez-Vilarrupla, N. Agell, and O. Bachs. 1999. The protein SET regulates the inhibitory effect of p21(Cip1) on cyclin E-cyclin-dependent kinase 2 activity. J. Biol. Chem. 274:33161-33165.
16. Funk, J. O., S. Waga, J. B. Harry, E. Espling, B. Stillman, and D. A. Galloway. 1997. Inhibition of CDK activity and PCNA-dependcnt DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes Dev. 11:2090-2100.
17. Gu, W., and R. G. Roeder. 1997. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90:595-606.
18. 1 cyclin-dependent kinases. Cell 75:805-816.
19. Harper, J. W., S. J. Elledge, K. Keyomarsi, B. Dynlacht, L. H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell, et al. 1995. Inhibition of cyclin-dependent kinases by p21. Mol. Biol. Cell 6:387-400.
20. Harris, L. C. 2005. MDM2 splice variants and their therapeutic implications. Curr. Cancer Drug Targets 5:21-26.
21. Hupp, T. R., D. W. Meek, C. A. Midgley, and D. P. Lane. 1992. Regulation of the specific DNA binding function of p53. Cell 71:875-886.
22. Iwakuma, T., and G. Lozano. 2003. MDM2, an introduction. Mol. Cancer Res. 1:993-1000.
23. Jackson, M. W., M. K. Agarwal, M. L. Agarwal, A. Agarwal, P. Stanhope-Baker, B. R. Williams, and G. R. Stark. 2004. Limited role of N-terminal phosphoserine residues in the activation of transcription by p53. Oncogene 23:4477-4487.
24. Jin, Y., H. Lee, S. X. Zeng, M. S. Dai, and H. Lu. 2003. MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J. 22:6365-6377.
25. Jones, D. L., R. M. Alani, and K. Munger. 1997. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes Dev. 11:2101-2111.
26. Kawai, H., D. Wiederschain, H. Kitao, J. Stuart, K. K. Tsai, and Z. M. Yuan. 2003. DNA damage-induced MDMX degradation is mediated by MDM2. J. Biol. Chem. 278:45946-45953.
27. Kubbutat, M. H., R. L. Ludwig, M. Ashcroft, and K. H. Vousden. 1998. Regulation of Mdm2-directed degradation by the C terminus of p53. Mol. Cell. Biol. 18:5690-5698.
28. Lambert, P. F., F. Kashanchi, M. F. Radonovich, R. Shiekhattar, and J. N. Brady. 1998. Phosphorylation of p53 serine 15 increases interaction with CBP. J. Biol. Chem. 273:33048-33053.
29. Lu, H., R. P. Fisher, P. Bailey, and A. J. Levine. 1997. The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. Mol. Cell. Biol. 17:5923-5934.
30. Maki, C. G., J. M. Huibregtse, and P. M. Howley. 1996. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res. 56:2649-2654.
31. Meek, D. W., and U. Knippschild. 2003. Posttranslational modification of MDM2. Mol. Cancer Res. 1:1017-1026.
32. Midgley, C. A., J. M. Desterro, M. K. Saville, S. Howard, A. Sparks, R. T. Hay, and D. P. Lane. 2000. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene 19:2312-2323.
33. Ohkubo, S., T. Tanaka, Y. Taya, K. Kitazato, and C. Prives. 2006. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53 dependent transcription. J. Biol. Chem. 281:16943-16950.
34. Ono, T., H. Kitaura, H. Ugai, T. Murata, K. K. Yokoyama, S. M. Iguchi-Ariga, and H. Ariga. 2000. TOK-1, a novel p21Cip1-binding protein that cooperatively enhances p21-dependent inhibitory activity toward CDK2 kinase. J. Biol. Chem. 275:31145-31154.
35. Pan, Y., and J. Chen. 2003. MDM2 promotes ubiquitination and degradation of MDMX. Mol. Cell. Biol. 23:5113-5121.
36. 2 checkpoint is maintained by redundant pathways. Mol. Cell. Biol. 19:5872-5881.
37. Rodriguez, M. S., J. M. Desterro, S. Lain, D. P. Lane, and R. T. Hay. 2000. Multiple C-terminal lysine residues target p53 for ubiquitin-proteasome-mediated degradation. Mol. Cell. Biol. 20:8458-8467.
38. Rousseau, D., D. Cannella, J. Boulaire, P. Fitzgerald, A. Fotedar, and R. Fotedar. 1999. Growth inhibition by CDK-cyclin and PCNA binding domains of p21 occurs by distinct mechanisms and is regulated by ubiquitin-proteasome pathway. Oncogene 18:4313-4325.
39. Russo, A. A., P. D. Jeffrey, A. K. Patten, J. Massague, and N. P. Pavletich. 1996. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. Nature 382:325-331.
40. Sdek, P., H. Ying, D. L. Chang, W. Qiu, H. Zheng, R. Touitou, M. J. Allday, and Z. X. Xiao. 2005. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol. Cell 20:699-708.
41. Shieh, S. Y., M. Ikeda, Y. Taya, and C. Prives. 1997. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 91:325-334.
42. St. Clair, S., L. Giono, S. Varmeh-Ziaie, L. Resnick-Silverman, W. J. Liu, A. Padi, J. Dastidar, A. DaCosta, M. Mattia, and J. J. Manfredi. 2004. DNA damage-induced downregulation of Cdc25C is mediated by p53 via two independent mechanisms: one involves direct binding to the cdc25C promoter. Mol. Cell 16:725-736.
43. Takenaka, I., F. Morin, B. R. Seizinger, and N. Kley. 1995. Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases. J. Biol. Chem. 270:5405-5411.
44. Thompson, T., C. Tovar, H. Yang, D. Carvajal, B. T. Vu, Q. Xu, G. M. Wahl, D. C. Heimbrook, and L. T. Vassilev. 2004. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J. Biol. Chem. 279:53015-53022.
45. Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844-848.
46. Vogelstein, B., D. Lane, and A. J. Levine. 2000. Surfing the p53 network. Nature 408:307-310.
47. 1 arrest in human cancer cells. Cancer Res. 55:5187-5190.
48. Wang, H., L. Nan, D. Yu, S. Agrawal, and R. Zhang. 2001. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin. Cancer Res. 7:3613-3624.
49. Wang, H., L. Nan, D. Yu, J. R. Lindsey, S. Agrawal, and R. Zhang. 2002. Anti-tumor efficacy of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer models: p53-dependent and p53-independent mechanisms. Mol. Med. 8:185-199.
50. Wang, H., S. Wang, L. Nan, D. Yu, S. Agrawal, and R. Zhang. 2002. Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: in vivo activity and mechanisms. Int. J. Oncol. 20:745-752.
51. Wang, H., D. Yu, S. Agrawal, and R. Zhang. 2003. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 54:194-205.
52. Wohlschlegel, J. A., B. T. Dwyer, D. Y. Takeda, and A. Dutta. 2001. Mutational analysis of the Cy motif from p21 reveals sequence degeneracy and specificity for different cyclin-dependent kinases. Mol. Cell. Biol. 21:4868-4874.
53. Würl, P., F. Bartel, A. Meye, M. Kappler, M. Bache, H. Schmidt, M. Schonfelder, and H. Taubert. 2002. Growth reduction of a xenotransplanted human soft tissue sarcoma by MDM2 antisense therapy via implanted osmotic minipumps. Int. J. Oncol. 20:1087-1093.
54. Zhang, H., G. J. Hannon, and D. Beach. 1994. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev. 8:1750-1758.
55. Zhang, Z., M. Li, H. Wang, S. Agrawal, and R. Zhang. 2003. Antisense therapy targeting MDM2 oncogene in prostate cancer: effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc. Natl. Acad. Sci. USA 100:11636-11641.
56. Zhang, Z., H. Wang, M. Li, S. Agrawal, X. Chen, and R. Zhang. 2004. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J. Biol. Chem. 279:16000-16006.
57. Zhou, R., R. Frum, S. Deb, and S. P. Deb. 2005. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Res. 65:1839-1848.